ArticleClinics (Sao Paulo, Brazil)2026
Dapagliflozin as an adjunct to insulin improves glycemic control, weight, and lipid profile with a superior safety profile in type 2 diabetes: a randomized trial.
Article in Clinics (Sao Paulo, Brazil), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the efficacy and safety of dapagliflozin-insulin combination in patients with Type 2 Diabetes Mellitus (T2DM).
methodsIn this 3-month, randomized controlled trial, 86 T2DM patients were allocated to either insulin monotherapy (Group A) or dapagliflozin-insulin combination (Group B). Primary endpoints included glycemic control (Fasting Blood Glucose [FBG], 2-hour Postprandial Blood Glucose [2hPBG], Hemoglobin A1c [HbA1c]), lipid profile (Total Cholesterol [TC], Triglycerides [TG], Low-Density Lipoprotein Cholesterol [LDL-C], High-Density Lipoprotein Cholesterol [HDL-C]), anthropometrics (Body Mass Index [BMI], Body Weight [BW]), blood pressure (Systolic Blood Pressure [SBP], Diastolic Blood Pressure [DBP]), and adverse events.
resultsAfter treatment, the combination therapy (Group B) demonstrated significantly greater improvements than insulin alone (Group A). Reductions in Group B versus Group A were: HbA1c (24.9%vs. 10.3%), FBG (23.6%vs. 5.6%), 2hPBG (25.1%vs. 13.7%), TC (35.1%vs. 16.9%), TG (15.9%vs. 11.0%), LDL-C (15.7%vs. 6.5%), SBP (7.3%vs. 3.2%), DBP (12.6%vs. 7.8%), BMI (9.8%vs. 4.3%), and BW (5.4%vs. 3.3%); while HDL-C increased more in Group B (16.3%vs. 9.9%). Group B demonstrated superior benefits in glycemic control, lipid profile, anthropometrics parameters and blood pressure reductions. All post-treatment between-group comparisons were statistically significant (p < 0.05). Critically, the incidence of adverse events was 71.4% lower in Group B, a statistically significant difference (p = 0.007).
conclusionsDapagliflozin as an adjunct to insulin provides superior multi-faceted metabolic benefits encompassing glycemic control, weight reduction, lipid improvement, and blood pressure lowering, coupled with a more favorable safety profile, supporting its inclusion in standard insulin regimens for T2DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.